木瓜直播

While suicide rates continue to rise nationwide, the has been declining. (Translational Psychiatry)

Patient-centered care is the focus of an update to an American Society for Radiation Oncology guideline on .

A new clinical guideline emphasizes an individualized approach to selecting contraceptive options for . (International Journal of Gynaecology and Obstetrics)

Restoring and regulating may help improve the clinical activity of immune checkpoint inhibitors. (Nature Immunology)

AstraZeneca said its antibody-drug conjugate datopotamab deruxtecan led to "clinically meaningful improvement" in overall survival (OS) versus chemotherapy for patients with .

Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy followed by adjuvant pembrolizumab led to significant improvement in OS for patients with high-risk early-stage Merck announced.

The FDA has expanded approval of the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) to include in adults.

Ikena Oncology announced the for IK-930, a TEAD1-selective Hippo pathway inhibitor, but patients whose cancers benefited from the agent in clinical trials will be able to continue the treatment.

The FDA announced that Sagent Pharmaceuticals voluntarily issued a nationwide recall of because of potential contamination with particulate matter.

The agency also granted accelerated approval to selpercatinib (Retevmo) for pediatric patients with .

Could a find a role in cancer prevention? (Science Advances)

Comment